Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

• Status: Completed
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Brii Biosciences Limited
• Collaborators: Alnylam Pharmaceuticals; Vir Biotechnology, Inc.

Criteria

Inclusion Criteria:

• Male or female age 18 - 65;

• Weight ≥ 40 kg to ≤ 125 kg;

• Chronic HBV infection as defined by a positive serum HBsAg for ≥ 6 months;

Exclusion Criteria:

• Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation;

• Significant fibrosis or cirrhosis;

• History or evidence of drug or alcohol abuse;

• History of intolerance to SC injection;

• History of chronic liver disease from any cause other than chronic HBV infection;

• History of hepatic decompensation;